BioNTech SE [BNTX] Revenue clocked in at $581.90 million, up 148.22% YTD: What’s Next?

BioNTech SE [NASDAQ: BNTX] traded at a high on 05/10/21, posting a 10.15 gain after which it closed the day’ session at $202.35. The company report on May 11, 2021 that Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years.

Data also submitted to European Medicines Agency (EMA) and other global regulators, with additional authorizations expected in coming weeks.

The results of the trading session contributed to over 7152816 shares changing hands. Over the past one week, the price volatility of BioNTech SE stands at 16.40% while the volatility over the past one month is 8.68%.

The market cap for BNTX stock reached $44.69 billion, with 314.43 million shares outstanding and 214.95 million shares in the current float. Compared to the average trading volume of 2.41M shares, BNTX reached a trading volume of 7152816 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about BioNTech SE [BNTX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNTX shares is $137.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNTX stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for BioNTech SE shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 01, 2020. While these analysts kept the previous recommendation, Berenberg raised their target price to Buy. The new note on the price target was released on August 03, 2020, representing the official price target for BioNTech SE stock. Previously, the target price had yet another raise from $71 to $105, while BofA Securities kept a Buy rating on BNTX stock.

The Average True Range (ATR) for BioNTech SE is set at 15.30, with the Price to Sales ratio for BNTX stock in the period of the last 12 months amounting to 76.81. The Price to Book ratio for the last quarter was 38.47, with the Price to Cash per share for the same quarter was set at 7.36.

How has BNTX stock performed recently?

BioNTech SE [BNTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.14. With this latest performance, BNTX shares gained by 65.67% in over the last four-week period, additionally plugging by 119.95% over the last 6 months – not to mention a rise of 310.95% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNTX stock in for the last two-week period is set at 69.36, with the RSI for the last a single of trading hit 69.02, and the three-weeks RSI is set at 69.16 for BioNTech SE [BNTX]. The present Moving Average for the last 50 days of trading for this stock 130.27, while it was recorded at 180.34 for the last single week of trading, and 101.48 for the last 200 days.

BioNTech SE [BNTX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BioNTech SE [BNTX] shares currently have an operating margin of -55.27 and a Gross Margin at +87.76. BioNTech SE’s Net Margin is presently recorded at +3.15.

Return on Total Capital for BNTX is now -23.29, given the latest momentum, and Return on Invested Capital for the company is 1.34. Return on Equity for this stock inclined to 1.55, with Return on Assets sitting at 0.93. When it comes to the capital structure of this company, BioNTech SE [BNTX] has a Total Debt to Total Equity ratio set at 17.51. Additionally, BNTX Total Debt to Total Capital is recorded at 14.90, with Total Debt to Total Assets ending up at 10.36. Long-Term Debt to Equity for the company is recorded at 16.84, with the Long-Term Debt to Total Capital now at 14.33.

Reflecting on the efficiency of the workforce at the company, BioNTech SE [BNTX] managed to generate an average of $8,926 per employee. Receivables Turnover for the company is 4.86 with a Total Asset Turnover recorded at a value of 0.29.BioNTech SE’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.80.

Earnings analysis for BioNTech SE [BNTX]

With the latest financial reports released by the company, BioNTech SE posted -0.29/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNTX.

Insider trade positions for BioNTech SE [BNTX]

There are presently around $5,325 million, or 11.00% of BNTX stock, in the hands of institutional investors. The top three institutional holders of BNTX stocks are: BAILLIE GIFFORD & CO with ownership of 6,738,012, which is approximately New of the company’s market cap and around 1.18% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 4,628,197 shares of the stock with an approximate value of $850.25 million in BNTX stocks shares; and FMR LLC, currently with $532.52 million in BNTX stock with ownership of nearly -35.624% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in BioNTech SE stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 123 institutional holders increased their position in BioNTech SE [NASDAQ:BNTX] by around 11,783,456 shares. Additionally, 79 investors decreased positions by around 7,389,904 shares, while 30 investors held positions by with 9,813,272 shares. The mentioned changes placed institutional holdings at 28,986,632 shares, according to the latest SEC report filing. BNTX stock had 75 new institutional investments in for a total of 8,948,251 shares, while 31 institutional investors sold positions of 1,021,410 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam